Vaccine

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development, today announced that Mikael Dolsten,...

Rapid Dose Therapeutics Corp. Announces Payment in Shares for Quarterly Interest on Secured Debt and Update on Shares for Debt Settlement with Creditors

Burlington, Ontario--(Newsfile Corp. - April 1, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today...

Unity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended Immunizations

Stay on TASK Infographic Infographic describing the four steps to being able to get vaccinated with confidence described by TASK...

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of...

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in...

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3),...

Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence’s Management Team as Chief Operating Officer

Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the...

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...

In-Licensing Opportunity: How a Pharma Leader Leveraged Scientific Innovation for Clinical and Commercial Success | DelveInsight

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity and aimed to...

error: Content is protected !!